(Reuters) - AS1404 is due to enter final Phase III trials next year and, if successful, could be the first in a new class of anti-cancer drugs designed to disrupt the flow of blood to tumours.
It works in a different way to Roche's established medicine Avastin, which also starves tumour cells of blood, and is expected to help the 25 to 40 percent of patients with squamous non-small cell lung cancer who cannot take Avastin.
Read more at Reuters.com Mergers News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment